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Abstract 
Background 
Clinical trials are typically designed using the classical frequentist framework to constrain type I and 
II error rates. Sample sizes required in such designs typically range from hundreds to thousands of 
patients which can be challenging for rare diseases. It has been shown that rare disease trials have 
smaller sample sizes than non-rare disease trials. Indeed some orphan drugs were approved by the 
European Medicines Agency based on studies with as few as 12 patients. However, some studies 
supporting marketing authorisation included several hundred patients. In this work, we explore the 
relationship between disease prevalence and other factors and the size of interventional phase 2 
and 3 rare disease trials conducted in the US and/or EU. We downloaded all clinical trials from 
Aggregate Analysis of ClinialTrials.gov (AACT) and identified rare disease trials by cross-referencing 
MeSH terms in AACT with the list from Orphadata. We examined the effects of prevalence and 
phase of study in a multiple linear regression model adjusting for other statistically significant trial 
characteristics. 
 
Results 
Of 186941 ClinicalTrials.gov trials only 1567 (0.8%) studied a single rare condition with prevalence 
information from Orphadata. There were 19 (1.2%) trials studying disease with prevalence 
<1/1,000,000, 126 (8.0%) trials with 1-9/1,000,000, 791 (50.5%) trials with 1-9/100,000 and 631 
(40.3%) trials with 1-5/10,000. Of the 1567 trials, 1160 (74%) were phase 2 trials. The fitted mean 
sample size for the rarest disease (prevalence <1/1,000,000) in phase 2 trials was the lowest (mean, 
15.7; 95% CI, 8.7–28.1) but were similar across all the other prevalence classes; mean, 26.2 (16.1–
42.6), 33.8 (22.1–51.7) and 35.6 (23.3–54.3) for prevalence 1-9/1,000,000, 1-9/100,000 and 1-
5/10,000, respectively. Fitted mean size of phase 3 trials of rarer diseases, <1/1,000,000 (19.2, 6.9–
53.2) and 1-9/1,000,000 (33.1, 18.6–58.9), were similar to those in phase 2 but were statistically 
significant lower than the slightly less rare diseases, 1-9/100,000 (75.3, 48.2–117.6) and 1-5/10,000 
(77.7, 49.6–121.8), trials. 
 
Conclusions 
We found that prevalence was associated with the size of phase 3 trials with trials of rarer diseases 
noticeably smaller than the less rare diseases trials where phase 3 rarer disease (prevalence 
<1/100,000) trials were more similar in size to those for phase 2 but were larger than those for 
phase 2 in the less rare disease (prevalence 1/100,000) trials. 
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1 Background 
The European Union (EU) define a disease as being rare if the prevalence is not more than 5 in 
10,000 which affects approximately 254,500 people throughout the EU member countries whose 
total population is approximately 509 million [1]. The United States (US) define a disease as being 
rare if it affects fewer than 200,000 person in the US [2]. This is equivalent to 62 people in 100,000 in 
2015 [1]. In such circumstances, one may still be able to design a randomised controlled trial (RCT) 
based on the classical frequentist framework where, for example, the sample size for a two sample 
t-test with a 0.05 two-sided type I error rate and 0.90 power to detect a standardized effect size of 
0.20 is 1052.  
 
As stated in the “Guideline on clinical trials in small populations” by the European Medicines 
Agency/Committee for Medicinal Products for Human Use (EMA/CHMP), most orphan indications 
submitted for regulatory approval are based on RCTs [3]. Deviation from the perceived gold standard 
RCT is uncommon. This statement is supported by Buckley [4], who presented a short summary of 
clinical trials of drugs for rare diseases approved by the European regulator between 2001 and 2007. 
Some of these studies had as few as 12 patients and some several hundreds. For example, the 
marketing authorisation of carglumic acid for hyperammonaemia due to N-acetyl glutamate 
synthase deficiency was supported by one pharmacokinetic study with 12 patients and one 
retrospective study with 20 patients. In contrast, the marketing authorisation of sorafenib tosilate 
for renal cell and hepatocellular carcinomas was supported by one phase III renal trial with 903 
patients and one phase III hepatic trial with 602 patients. 
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Bell and Tudur Smith compared the characteristics of rare and non-rare disease clinical trials 
registered in ClinicalTrials.gov [5]. In their review, 64% of rare disease trials had fewer than 50 
patients compared to 38% of non-rare disease trials. Only 14% of rare disease trials had more than 
100 patients compared to 36% of non-rare disease trials. These results suggest that large studies are 
possible when studying indications for rare diseases. However, many rare diseases affect 1 in 
100,000 or fewer [6] limiting the potential pool of patients that would be eligible and willing to be 
recruited to trials. Accordingly, the design and analysis of clinical trials for these diseases becomes 
more challenging. In addition, as stated in the EMA/CHMP guideline, the prevalence of the disease 
may constrain to varying degrees the design, conduct, analysis and interpretation of these trials. 
 
In this paper we examine the association between the disease prevalence and sample size for clinical 
trials in rare diseases allowing for other factors, extending the work of Bell and Tudur Smith but 
without comparison between non-rare and rare disease trials. Our analysis is based on data from the 
Aggregate Analysis of ClinicalTrials.gov database (AACT) [7], a registry of more than 180,000 clinical 
studies and Orphadata [8], a portal for information of rare diseases and their prevalence. 
  
2 Materials and Methods 
2.1 Aggregate Analysis of ClinicalTrials.gov database (AACT) 
The database from ClinicalTrials.gov, Aggregate Analysis of ClinicalTrials.gov (AACT), is comprised of 
clinical studies registered up to 27 September 2015 [7, 9]. A comprehensive documentation of 
definitions of all variables is available on the ClinicalTrials.gov Protocol Registration System [10].  
Each study in AACT may have information on the study characteristics such as types of study 
(interventional, observational, patient registry, or expanded access), phase of investigation (phase 1, 
2, 3 or 4), design features of the study such as the intervention model (crossover, factorial, parallel 
or single group assignment), masking (double blind, single blind or open label), allocation 
(randomized, non-randomized), primary endpoint (e.g., efficacy, safety, pharmacodynamics, 
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pharmacokinetics), number of intervention arms, and lead sponsor (industry, National Institutes of 
Health (NIH), US Federal Agency or other).  Also recorded is the date that enrolment began, primary 
completion date which is either the date when the final subject was examined or received an 
intervention for the purpose of data collection for the primary outcome or the anticipated date 
when this will occur, the actual sample size upon completion of the study or the anticipated sample 
size for trials that have not yet completed recruitment, recruitment status, whether or not the trial 
had a Data Monitoring Committee (DMC), whether or not the intervention was Food and Drug 
Administration (FDA) regulated, and, for a trial with an FDA-regulated intervention whether or not 
this was an “applicable clinical trial” as defined under Section 801 of FDA Amendments Act 
(FDAAA801). Briefly, an applicable clinical trial is one where the trial has one or more sites in the US, 
is conducted under an FDA investigational new drug application or the regulated intervention (drug, 
biological product or device) is manufactured in the US and is to be exported for research. 
  
Other clinical characteristics available from the AACT include the inclusion/eligibility criteria such as 
gender (female, male or both), age range of participants and whether or not the trial accepts healthy 
volunteers. The primary conditions or diseases being studied were recorded using the National 
Library of Medicine’s (NLM) Medical Subject Headings (MeSH) when possible.   
 
 
2.2 Orphadata 
Orphadata is a database of rare diseases compiled by the 40-country consortium Orphanet 
coordinated by the French National Institute of Health and Medical Research (INSERM) team [11]. It 
gives an inventory of rare diseases comprised of the typology of the disease and cross-referencing 
with external classifications such as the 10th International Classification of Diseases (ICD-10), Online 
Mendelian Inheritance in Man (OMIM), United Medical Language System (UMLS), MeSH and 
Medical Dictionary for Regulatory Activities (MedDRa). Orphadata, also contains epidemiology data 
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such as type of prevalence (point prevalence, birth prevalence, lifetime prevalence, incidence, or the 
number of cases/families, see Posada de la Paz et al. for definition of types of prevalence [12]) by 
geographical area (e.g., country, continent), average age of onset, clinical signs, and for some rare 
disorders, the associated genes and their influences in the pathogenesis of the disease [8]. 
Prevalence data for rare conditions in Orphadata are classified into six possible classes, namely, 
<1/1,000,000, 1-9/1,000,000, 1-9/100,000, 1-5/10,000, 6-9/10,000, >1/1,000, along with “not yet 
documented” and “unknown”. These data were obtained from either published literature or 
registries. Some information from published literature were yet to be validated by experts and so 
the entry was recorded as “Not yet validated”. For our work, we focus on the epidemiological data 
such as type and class of prevalence data and geographical area. 
 
Figure A1 (see Appendix A1) shows that there were 9199 rare diseases in Orphadata but only 5029 
(55%) had prevalence information. Of the 5029 diseases about one third (1585) of the entries had 
only one type of prevalence entry. The other 3444 had more than one type of prevalence entry 
giving a total of 10008 entries. A total of 8060 of these entries had been validated. 
 
2.3 Merging of AACT and Orphadata 
AACT and Orphadata were downloaded on 9 May 2016. A technical description of the merging of 
AACT and Orphadata is given in Appendix A2. For our analysis, we identified trials in AACT by 
matching the MeSH terms in AACT with those in Orphadata. Trials in AACT with MeSH terms not in 
Orphadata were declared as trials not studying non-rare diseases. In our work, focus was restricted 
to interventional phase 2 and/or 3 trials in a single rare disease with treatment as the primary 
purpose conducted in the US only, EU only (member states of the EU and associated countries) or in 
both US and EU. We restricted trials to these countries only because we believe that rare disease 
prevalence was well estimated and homogeneous in these countries whereas the prevalence for 
some diseases varies very considerably between US/EU and some other countries. Trials studying 
7 
 
more than one rare disease were excluded from further analyses because it was unclear which 
disease prevalence data should be used. 
 
For each trial, the prevalence of the disease in the countries where the trial took place was 
identified.  If there was more than one prevalence entry for the disease in the trial location, the 
prevalence was used based on the following variables (in decreasing order of preference): 
1.  Validation status: (i) validated, and (ii) not yet validated. 
2. Type of prevalence: (i) point prevalence, (ii) lifetime prevalence, (iii) prevalence at birth, (iv) 
annual incidence, and (v) cases/families. 
If no prevalence information was available for the disease in the trial location then the prevalence 
for a neighbouring country or another country from the same geographic region was used. See 
Appendix A2 for details on the merging of diseases and their class of prevalence. Note that if only 
the number of cases/families was recorded, the prevalence was assumed to be <1/1,000,000. 
 
Figure A2 (see Appendix A3) shows that there were 186941 trials in ClinicalTrials.gov and of these 
28547 were interventional phase 2 and/or 3 treatment trials conducted in the US and/or EU. There 
were 2136 trials that studied rare conditions only and of these 2019 studied one rare condition only. 
Of the 2019 trials of a single disease in the Orphadata database, 415 were excluded from analyses; 
16 because they had prevalence greater than 5/10,000 (because a rare disease is defined to affect 
less than 5/10,000) and 399 because they had no prevalence information. An additional thirty seven 
trials studied conditions with prevalence recorded as “Unknown”. These were excluded from the 
analysis reported in the main paper, which is therefore based on a total of 1567 trials, but are 
included in analyses reported in the Appendices. 
 
2.4 Statistical Analyses 
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The characteristics of trials of diseases in each prevalence category were summarised, either as 
frequencies and percentages for categorical data or means and standard deviations for continuous 
data. In addition to the characteristics listed in Section 2.1 above, the duration of collection of 
primary outcome were calculated, from the date that enrolment to the protocol begins to either the 
actual completion date or anticipated date where trials were ongoing. Phase 2/3 trials were grouped 
with phase 3 trials; these will be collectively referred as phase 3 henceforth.   
 
Analysis of variance and linear regression models were used to investigate the association between 
prevalence and trial characteristics and the sample size. This was the actual sample size for 
completed trials where this was available and the anticipated sample size for non-completed trials. 
As skewness of the distribution of the sample size was anticipated, the dependent variable in the 
analyses was taken to be the logarithm of the trial sample size. The fitted mean sample size and its 
95% confidence interval (CI) were then back transformed by taking the exponential of the fitted 
values. The independent variables used for the regression analyses are marked with * in Table A3 
(see Appendix A4). A few variables were not used for this analysis: whether or not the trial accepts 
healthy volunteers, whether or not that a trial with an FDA-regulated intervention was a FDAAA801 
clinical trial, masking, allocation, primary endpoint, overall recruitment status and primary 
completion duration. These variables were not included in the regression models because the 
number of trials with healthy volunteers was very small (<2%; variable, whether or not the trial 
accepts healthy volunteers), because FDAAA801 trials are a subset of those for which the 
intervention was FDA regulated, because masking, allocation, primary endpoint were highly collinear 
with phase, because overall recruitment status was not a design feature and because primary 
completion duration was closely related to sample size. It was expected that prevalence class and 
phase of study would influence the choice of sample size and so to explore the effect of other 
covariates, these were added in turn to a model that included prevalence class, phase of study and 
the interaction of these two covariates. Covariates were considered to have a significant effect on 
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the sample size if they were significant at the p < 0.05 level. This relatively stringent condition was 
used as we were more concerned with determining which factors are associated with sample size 
than in prediction or adjusting for all possible factors. The effects of prevalence class and phase of 
study were then considered based on both an unadjusted model and a model adjusting for all other 
significant covariates. Pairwise comparison were used to investigate further the difference between 
levels of a covariate. 
 
3 Results 
3.1 Trial Characteristics 
Table A3 (see Appendix A4) shows characteristics and features of the 1567 trials for each prevalence 
class. The number of trials studying conditions with prevalence <1/1,000,000, 1-9/1,000,000, 1-
9/100,000, and 1-5/10,000 were 19 (1.21%), 126 (8.04%), 791 (50.48%), and 631 (40.27%), 
respectively. Of the 1567 trials, 1361 (87%) were conducted in one country only; US only (m = 823, 
53%) or one European country only (m = 538, 34%). This seems to suggest that trials were still 
frequently conducted in one country despite the appeal of accessibility to a larger pool of eligible 
patients in multi-nation trials. 
 
Figure 1 shows the sample size of phase 2 trials (Fig. 1 (a)), and phase 3 (combined phase 2/3 and 
phase 3) trials (Fig. 1 (b)) for each prevalence class separately for completed and ongoing trials. 
Within each prevalence class the small plotted symbols represent the observed data, with triangles 
giving actual and dots giving anticipated sample sizes. The large plotted red diamonds give the mean 
values while the box plots show the median, first and third quartiles. The whisker shows the 
minimum (maximum) observation above (below) the 1.5 times the interquartile range. Note that the 
lower whisker appears to include a wider range because the y-axis is in log-scale. 
< Figures 1 (a) and (b) about here > 
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As expected there were more phase 2 than phase 3 trials, and the median sample size for phase 3 
trials was higher than those in phase 2. Fig. 1 shows that the median of actual sample size from 
completed trials was generally lower than the median of anticipated size and that there is a wide 
spread of actual/anticipated sample sizes. Fig. 1 (a) shows sample sizes for phase 2 trials, indicating 
that there was no strong association between prevalence and sample size. About 75% of the rarer 
diseases (<1/1,000,000 and 1-9/1,000,000) trials had size less than 50; actual median size, 15 
(interquartile range, IQR, 8–55), anticipated median size, 20 (IQR, 10–30) for prevalence 
<1/1,000,000 and actual and anticipated median sizes for prevalence 1-9/1,000,000 were 22 (IQR, 
15–40) and 38 (IQR, 23.5–77.5), respectively. This was also the case for more than half of the trials of 
less rare diseases: 1-9/100,000; actual and anticipated median sizes were 36 (IQR, 20–64) and 47 
(IQR, 30–70), respectively; and 1-5/10,000; actual and anticipated median sizes were 38 (IQR, 20–67) 
and 46 (IQR, 30–80). The third quartile of the boxplots was below 100 showing that less than 25% 
trials across different classes of prevalence had size greater than 100. 
 
Fig. 1 (b) shows sample sizes for phase 3 trials. There were fewer number of phase 3 rarer diseases 
trials (m = 26) than phase 2 (m = 81). Here there is slightly more indication that the sample size is 
larger for trials in less rare diseases. The actual and anticipated median sizes for diseases with 
prevalence <1/1,000,000 were 39.5 (IQR, 36–43) and 10 (IQR, 10–10), respectively; for diseases with 
prevalence 1-9/1,000,000 were 74.5 (IQR, 22–100) and 62 (IQR, 20–100), respectively; for diseases 
with prevalence 1-9/100,000 were 112 (IQR, 34.5–301) and 180 (IQR, 86–340), respectively; and for 
diseases with prevalence 1-5/10,000 were 122.5 (IQR, 46–256) and 255 (IQR, 80–440), respectively. 
 
3.2 Main Analysis 
Covariates that were found to be statistically significantly related to sample size were inclusion 
criteria gender and age, whether or not the trial had a DMC, whether or not the intervention was 
FDA regulated, intervention model, trial regions, number of countries participating in the trial, year 
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that enrolment to the protocol begins and number of treatment arms (see Table A4 in Appendix A5). 
Trials that recruited females only had the highest fitted mean size (58.12; 95% confidence interval, 
CI, 44.23–76.38) whilst those that recruited male only had the lowest (21.09; 95% CI, 14.04–31.69). 
This effect may be confounded by the indication or disease that affects females or males only but 
not both. Unsurprisingly, trials for children only (term new born infants to adolescents up to 18 
years) had the smallest estimated size (36.29; 95% CI, 28.03–46.99). We might have expected the 
age group 18-65 years old (adults only) to have the most patients and thus trials for this age range 
would be the largest. However, the estimated mean was 58.49 (95% CI, 45.34–75.45) whereas trials 
for elderly only (65 years or older) had the largest size (89.17; 95% CI, 58.86–135.08). Trials not of an 
FDA regulated intervention were marginally larger, mean, 52.30 (95% CI, 43.72–62.56) compare to 
those with FDA regulated intervention, 46.20 (95% CI, 38.77–55.06). Trials with DMC had larger size 
(52.43; 95% CI, 44.06–62.38 vs. 42.95; 95% CI, 35.92–51.36). Trials with a factorial design had the 
largest sample size (139.83; 95% CI, 56.36–346.91) compared to parallel assigned trials (71.38; 95% 
CI, 60.45–84.28), single group (34.28; 95% CI, 29.05–40.46) and crossover trials (28.63; 95% CI, 
21.84–37.53). There was no significant relation between lead sponsor and sample size. Trials 
conducted in the EU had the largest sample size (71.63; 95% CI, 55.99–91.64) followed by trials 
conducted in one European country only (49.77; 95% CI, 41.55–59.62), in the US and EU (46.29; 95% 
CI, 35.40–60.53) and in the US only had the smallest (42.50; 95% CI, 35.57–50.79). There seemed to 
be a slight decrease of sample size for trials in which enrolment started from year 2005 than those 
before then. Number of treatment arms in a trial affects the sample size required with trials with 
more arms tending to have larger sample size. The estimated increase in sample size per arm was 
14%. 
 
Figure 2 shows the fitted mean sample size (back transformed from logarithmic values), together 
with 95% confidence intervals, for trials in different prevalence class and phase of trial after 
adjusting for the covariates listed in the preceding paragraph. Effects of prevalence and phase were 
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statistically significant after adjusting for the other covariates, p values were <0.0001 and 0.0006, 
respectively, and the interaction between prevalence and phase was close to significance, p = 
0.0828. It is interesting to note from Fig. 2 that there is no apparent effect of prevalence in phase 2 
trials. From Table 1, the fitted mean sample size for diseases with prevalence <1/1,000,000 in phase 
2 was the lowest, 26.96 (95% CI, 14.74–49.31). Fitted mean sizes across the other prevalence classes 
were similar; 49.04 (95% CI, 29.87–80.51), 58.70 (95% CI, 38.14–90.32) and 59.42 (95% CI, 38.62–
91.43) for prevalence 1-9/1,000,000, 1-9/100,000 and 1-5/10,000, respectively. There is an apparent 
effect of prevalence in phase 3 trials (Fig. 2), where the trial size for diseases that are in the slightly 
less rare (1-9/100,000 and 1-5/10,000 prevalence classes) tended to be larger than those for the 
rarer diseases (<1/1,000,000 and 1-9/1,000,000 prevalence classes). The fitted mean sample sizes 
were 30.37 (95% CI, 10.37–88.92), 62.21 (95% CI, 34.40–112.49), 138.28 (95% CI, 88.39–216.34) and 
145.86 (95% CI, 92.79–229.30) for prevalence <1/1,000,000, 1-9/1,000,000, 1-9/100,000 and 1-
5/10,000, respectively. In pairwise comparisons between <1/1,000,000, and 1-9/100,000 and 1-
5/10,000, the differences were statistically significant, p = 0.0047 and 0.0039, respectively (results 
not shown). The differences between 1-9/1,000,000, and 1-9/100,000 and 1-5/10,000 were also 
statistically significant, p < 0.0001 in both pairwise comparisons (result not shown). Note that the 
sizes for rarer diseases (< 1/1,000,000 and 1-9/1,000,000 prevalence classes) in phase 3 were also 
similar to those in phase 2. Although the wide variation in sample sizes and the relatively small 
numbers of trials for some prevalence classes leads to wide confidence intervals, similar conclusions 
can be drawn to those given above based on Fig. 1 and the fitted regression model with class of 
prevalence, phase of trial and the interaction between prevalence and phase (Table 1).  
< Figure 2 about here > 
 
Table 1 Fitted mean of sample size and 95% confidence interval back transformed from logarithmic 
values, type III F statistic and the corresponding p value of the effect of class of prevalence on 
sample size adjusting for phase and interaction between prevalence and phase, and without 
adjustment for other covariates and with adjustment for other covariatesa. 
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95% CI F test p value 
Prevalence class 
   
17.38 <.0001 
   
20.73 <.0001   
< 1/1,000,000 19 21.21 (11.63–38.67) 
  
18 28.61 (14.43–56.73) 
  
  
1-9/1,000,000 88 40.57 (32.18–51.14) 
  
66 55.23 (33.76–90.37) 
  
  
1-9/100,000 587 74.19 (67.71–81.29) 
  
483 90.09 (58.66–138.36) 
  
  
1-5/10,000 454 86.37 (78.32–95.25) 
  
359 93.10 (60.58–143.08) 
  
             
Phase of investigationb 
   
21.56 <.0001 
   
324.97 <.0001 
  
Phase 2 841 32.84 (28.61–37.69) 
  
677 46.34 (29.86–71.90) 
  
  
Phase 3 307 71.50 (53.05–96.38) 
  
249 78.57 (47.48–130.02) 
  
           
PrevalencePhase 
   
6.40 0.0003 
   
2.75 0.0415  
P
h
as
e 
2
 < 1/1,000,000 16 18.05 (11.20–29.09) 
  
15 26.96 (14.74–49.31) 
  
 
1-9/1,000,000 65 35.23 (27.80–44.65) 
  
48 49.04 (29.87–80.51) 
  
 
1-9/100,000 442 41.52 (37.92–45.47) 
  
365 58.70 (38.14–90.32) 
  
 
1-5/10,000 318 44.04 (39.57–49.02) 
  
249 59.42 (38.62–91.43) 
  
              
P
h
as
e 
3
 < 1/1,000,000 3 24.92 (8.28–75.06) 
  
3 30.37 (10.37–88.92) 
  
 
1-9/1,000,000 23 46.71 (31.37–69.56) 
  
18 62.21 (34.40–112.49) 
  
 
1-9/100,000 145 132.56 (113.12–155.35) 
  
118 138.28 (88.39–216.34) 
  
 
1-5/10,000 136 169.39 (143.80–199.53) 
  
110 145.86 (92.79–229.30) 
  
Footnote: 
a Gender, age, whether or not the trial had a DMC, whether or not the intervention was FDA regulated, 
intervention model, trial regions, number of countries participating in the trial, year that enrolment to the 
protocol begins and number of arms. 
b As defined by the US FDA for trials involving investigational new drugs. 
 
The R-squared statistic, an indication of the proportion of variability of fitted log sample size by the 
prevalence, phase, interaction between prevalence and phase and the other covariates was 0.4184. 
This is small despite the large number of regressors in the model, suggesting that there appears to 
be a lot of unexplained variability. 
 
3.3 Sensitivity Analysis 
About one third of the trials (m = 587, 37%) used parallel assignment and about half (m = 792, 51%) 
used single group assignment. We performed sensitivity analyses with parallel 2-arm trials only and 
single group assignment (1-arm) trials only to investigate the effect of prevalence and phase of study 
adjusted by covariates on sample size. 
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For the analysis of parallel 2-arm trials only, we also included the types of arm (experimental, active 
comparator, placebo comparator, sham comparator, no intervention or others) as one of the 
covariates that may be associated with sample size. The possible combinations of 2-arm trials are: 
experimental vs. placebo (m = 88), experimental vs. standard (active comparator, no intervention, 
others) (m = 139), experimental vs. experimental (m = 49) and non-experimental vs. non-
experimental (m = 75). There were 354 parallel 2-arms trial and Table A5 (Appendix A6) shows 
covariates that were statistically significant related to sample size: gender, age, whether or not the 
trial had a DMC, trial regions, number of countries participating in the trial and types of arm. The 
fitted sample size for trials where the experimental arm vs. the standard arm was the highest, mean 
106.78 (95% CI, 83.63–136.33). Fitted mean sample sizes for trials across the other types of 2-arm 
were very similar; 52.82 (95% CI, 41.54–67.17), 53.44 (95% CI, 39.86–71.63) and 59.78 (95% CI, 
45.57–78.43) for experimental vs. placebo, experimental vs. experimental and non-experimental vs. 
non-experimental, respectively. Effects of prevalence class and phase of trial after adjusting for all 
the significant covariates on parallel 2-arm trials were statistically significant, p = 0.0004 and 0.0036, 
respectively (see, Table A6, Appendix A7). However, the interaction between prevalence and phase 
was not, p = 0.3727.  
 
There were 527 single group (1-arm) trials and Table A7 (Appendix A8) shows that lead sponsor, trial 
regions, number of countries participating in the trial and year that enrolment to the protocol began 
were significantly related to sample size. Only effects of prevalence and interaction between 
prevalence and phase were significant after adjusting for all significant covariates (p < 0.0001 and 
0.0013, respectively, see Table A6). Effects of phase of study was not statistically significant (p = 
0.2873). Overall, we observed similar trend where sample size is affected by prevalence where as 
the prevalence increases, mean sample size increases with a more noticeable difference in phase 3 
trials (see Fig. A8 in Appendix A9). 
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Discussion 
We found that a majority of trials were conducted in one country only regardless of the disease 
prevalence. This is slightly surprising given the opportunity in multi-nation trials to recruit more 
patients. Further investigation may be necessary to understand why multi-nation trials were not 
conducted more frequently. 
 
We also found that the actual sample size for completed trials was generally smaller than the 
anticipated trial size for ongoing trials. This supports results shown by Bell and Tudur Smith where 
there were more rare disease trials (35%) with actual enrolment of 50 or less and 29% of rare 
disease trials with anticipated enrolment of 50 or less [5]. This could be indicative of an ambition to 
complete large trials in rare disease populations that are difficult to achieve in practice. 
 
Sample sizes for trials in rare diseases were statistically significantly related to gender, age, whether 
or not the trial had a DMC, whether or not the intervention was FDA regulated, intervention model, 
trial regions with at least one participating centre, number of countries participating in the trial, year 
that enrolment to the protocol began and number of treatment arms.  
 
Trials enrolling males only were on average smaller than those that enrolled either females only or 
both sexes. Trials enrolling females only had slightly larger size than those that enrolled both sexes 
but this was not statistically significantly different. We expected that trials enrolling males only and 
females only to have smaller size because when the eligibility criteria is restrictive, the population is 
more homogeneous and less variable in effectiveness, thus smaller sample size may be sufficient. 
Further inspections revealed that of the 79 trials with females only, 78% (m = 62) of them were in 
phase 2 and 89% (m = 70) were for diseases with prevalence 1-5/10,000. There were only 25 trials 
with males only and 76% (m = 19) were in phase 2 and only 36% (m = 9) were for diseases with 
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prevalence 1-5/10,000. The small number of less rare diseases for males might have influenced the 
average sample size in male-only trials as shown in Table A9 (Appendix A10), a list of diseases by 
phase for females and males only. Of note is that most of these trials were in diseases that affect 
one sex only; all of the male-only trials were X-linked disorders whereas almost all of the female-only 
trials affected females only. A few of these trials were in disorders for pregnant women only. Further 
research is necessary to investigate and identify other factors that could explain this difference.  
 
Similarly, we expected trials enrolling various age groups to have larger sample sizes than those that 
recruited children only, adults only or elderly only because by expanding the sampling pool more 
patients could be recruited. However, on average trials recruiting multiple age groups were slightly 
smaller than adults-only and elderly-only trials.  
 
Unsurprisingly, trials with factorial design had larger sample size than single group and crossover 
trials since in a factorial design a few combinations of interventions are tested at the same time. 
Diseases that employed the factorial design had prevalence greater than 1/100,000 (the less rare 
diseases) suggesting that sophisticated designs could be used when possible. However, the most 
frequently used intervention model for the rarer diseases (prevalence <1/100,000) was single group 
assignment and the average sample size was less than 35. The levels of evidence from these trials 
may not be as high quality as the gold standard RCT. The EMA has indicated that prevalence of 
disease could constrain the design, conduct and analysis of trials for small populations and the 
EMA/CHMP guideline suggested that novel approaches could be considered in situations when it is 
difficult to recruit large number of patients [3]. This in turn presents a challenge of developing new 
methodology for trials in small populations. In response to this challenge, three collaborative 
research projects (Asterix, IDeAl and InSPiRe) are working on methods for clinical trials in the small 
population setting [13].  
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The main analysis and sensitive analyses with parallel 2-arm trials only and single group (1-arm) trials 
only showed that generally, the mean sample size was affected by prevalence where mean sample 
size increases as prevalence increases. The increase was noticeably larger in phase 3 trials compare 
to phase 2. However, due to small number of trials in some classes, it is difficult to make 
comparisons.  
 
The generalisability of the results obtained in this study rely on the extent to which trials included in 
the database are representative. Although institutions such as the International Committee of 
Medical Journal Editors (ICMJE) require certain studies to be registered either in ClinicalTrials.gov or 
other equivalent registries [14, 15], it seems likely that certain types of trials are more likely to be 
registered, especially, efficacy trials in serious or life-threatening diseases with investigational new 
drugs regulated by the FDA and EMA. This is a strength of this research as we concentrated on 
interventional phase 2 and/or 3 trials where there would be better coverage. However, phase 2 
and/or 3 trials taking place in EU site(s) initiated after 2011 may not be registered in 
ClinicalTrials.gov but in the EU Clinical Trials Register which was launched on 22 March 2011 [16]. 
 
A limitation with our study is the potential selection bias because we included only trials conducted 
in the US and/or the EU. This is a necessary measure to exclude trials studying diseases with low 
prevalence in the US/EU but high prevalence elsewhere. For example, there was a multi-centre 
interventional trial on tuberculosis with locations in the US, United Kingdom and Peru. The annual 
incidence in these countries are 1-9/100,000, 1-5/10,000 and >1/1,000, respectively [8, 17].  
 
Another possible limitation with our study is that we considered a condition to be rare if information 
on prevalence was listed in Orphadata. This database is updated on a regular basis and some 
conditions may have been missed out or with no prevalence information. Table A10 in Appendix A11 
provides a list of trials in the AACT database where the conditions studied were listed in Orphadata 
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but for which no value of prevalence is given. Prevalence of some diseases changes over time and 
because the prevalence information in Orphadata is updated regularly, old prevalence data are not 
retained. This presents a weakness to the study as trials studying rare diseases prior to 2016 were 
assumed to have updated prevalence. 
 
As explained in the methods section, we have used point prevalence to classify diseases into 
prevalence classes where this is available. In some cases, some other measure of prevalence has 
been used. In this project diseases are classified into groups according to their prevalence value and 
because of categorising continuous variable we have lost some information. However, this is a 
necessary pragmatic approach so that ultra rare diseases where only number of cases/families were 
known could be included in the analysis. In these diseases it is unknown which denominator should 
be used to calculate the prevalence value but they could be classified as having prevalence 
<1/1,000,000, as is the practice in Orphadata. Our results depend to some extent on the choice of 
types of prevalence used but as the results presented are based on means from a number of studies, 
it is likely that conclusions are relatively robust.  
 
In our analysis we have grouped trials described as phase 2/3 by investigators with trials described 
as phase 3. This is a reasonable assumption because the eventual objective of both phase 2/3 and 
phase 3 trials is to test the study hypothesis whether or not the treatment is more effective with a 
plan to subsequently submit for regulatory approval. However, there may have been inconsistency 
in data entry by investigators with the definition given by US FDA. This is likely to introduce 
systematic bias. Theses inconsistencies are difficult to rectify as the registry does not require 
investigators to give details on the design and sample size calculation where detailed examinations 
could be performed to check if the objective of the design correspond to the US FDA definition. 
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The number of patients eligible for trials may also depend on whether the rare condition is acute or 
life threatening, so that only new cases can be recruited, or chronic, when it may be possible to 
sample from a larger population depending on the prevalence rather than the incidence rate. 
Further work should investigate the association of acuteness/chronicity of the condition on the trial 
sample size. 
 
We have focussed attention on the sample size of trials in rare diseases. The AACT database also 
contains additional data, for example on trial design features such as the intervention model 
(crossover, factorial, parallel or single group assignment), masking (double blind, single blind or open 
label), allocation (randomized, non-randomized), primary endpoint (e.g., efficacy, safety, 
pharmacodynamics, pharmacokinetics) and number of interventions in a trial. These might also vary 
with disease prevalence among rare disease trials. Investigation of such effects could be the subject 
of further work. 
 
Conclusions 
This study has investigated sample sizes for clinical trials in rare diseases using data from the AACT 
database from ClinicalTrials.gov and prevalence data from the Orphadata databases from Orphanet.  
These databases provide rich resources to understand and characterise clinical trials studying rare 
diseases or conditions. The inventory of rare disease in Orphanet is updated on a regular basis and 
the prevalence and other information of the diseases are based on published scientific articles. 
 
We have limited our analyses to phase 2, phase 2/3 or phase 3 trials with treatment as the primary 
purpose conducted in the US and/or EU (member states of the EU and associated countries). We 
found that where were very few multi-nation trials suggesting that the opportunities to conduct 
larger or ‘adequately’ size trials were underused.  We also found that the fitted mean sample sizes 
for rare disease trials do differ slightly between prevalence classes (the interaction between 
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prevalence and phase was close to significance) with slightly larger trials conducted in diseases with 
higher prevalence. This effect was most noticeable in phase 3 trials where sample sizes for the rarer 
diseases are similar to those for phase 2 trials, but are larger than those for phase 2 trials in the less 
rare of the rare diseases considered.  
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Figure legends: 
Figure 1 Jittered boxplot of (a) phase 2 and (b) phase 3 trials with either actual (brown triangle) or 
anticipated (blue dot) sample size by prevalence class. Each symbol represents one observation and 
the mean sample size is indicated by the red diamond. Number of trials contributing to the plot is 
given at the top row, median sample size in the second row, first quartile in the third row and third 
quartile in the last row of the bottom of each boxplot. 
 
Figure 2 Fitted mean of sample size and 95% confidence interval back transformed from logarithmic 
values by class of prevalence and phase of trial adjusted for interaction between prevalence, phase 
of study and the interaction between prevalence and phase, adjusted for gender, age, whether or 
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not the trial had a DMC, whether or not the intervention was FDA regulated, intervention model, 
trial regions, number of countries participating in the trial, year that enrolment to the protocol 
begins and number of arms. 
 
Figure A1 A breakdown of epidemiological data of rare diseases in Orphadata. 
Footnote: a Whether or not the rare disease has any prevalence data; b Number of prevalence data 
entries per rare disease (extracted from literature); c Whether or not the given prevalence value is 
validated; d The subtype of prevalence information by geographical area. 
 
Figure A2 A breakdown of trials in ClinicalTrials.gov included in final analyses. 
Footnote: a The primary purpose of the trial; b A treatment-purpose trial is to evaluate one or more 
interventions for treating a disease, syndrome or condition; c Phase of investigation as defined by 
the US FDA; d For trials that do not involve drug or biologic products (e.g., behavioural 
interventions); e Primary disease or condition being studied in the trial. The terms of the conditions 
should follow the National Library of Medicine’s Medical Subject Headings (MeSH) where possible; f 
Trials studying non-rare disease(s)/condition(s); g Trials studying both rare and non-rare 
disease(s)/condition(s); h Number of rare disease(s)/condition(s) being studied in a trial. i Estimated 
prevalence from Orphanet; j The rare disease/condition has no prevalence data from Orphanet. 
 
Figure A3 Fitted mean of sample size and 95% confidence interval back transformed from 
logarithmic values by class of prevalence and phase of trial adjusted for interaction between 
prevalence, phase of study and the interaction between prevalence and phase for parallel 2-arm 
trials only (blue) and single group (1-arm) trials only (brown). Both fitted models were adjusted for 
other covariates (see Table A6). 
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Appendices 
Appendix A1 
< Figure A1 about here > 
 
Appendix A2 Merging of AACT and Orphadata 
Data from AACT is supplied as delimited text files and Orphadata were downloaded as Extensible 
Markup Language (XML) files. A database schema was first derived from evaluating the content of 
each text files in order to identify the database requirements. A SQL Server Integration Services 
(SSIS) program was then created to map the text files to the database schema and to extract and 
load the data into the database. A random sample of data from each text file was used to check 
against the database to verify data integrity. The Orphadata database schema was modified to 
include two additional tables to store disorder and prevalence data. An Extensible Stylesheet 
Language Transformation (XSLT) was created to parse the XML to create SQL insert statements for 
each disorder and prevalence entry. Data integrity was checked again by taking a random sample 
from the original XML files to compare against the data inserted into the database. 
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For each trial, the prevalence of the disease in the countries where the trial took place was 
identified. If there was more than one prevalence entries for the disease in the trial location, the 
prevalence was used based on the following variables (in decreasing order of preference): 
1.  Validation status: (i) validated, and (ii) not yet validated. 
2. Type of prevalence: (i) point prevalence, (ii) lifetime prevalence, (iii) prevalence at birth, (iv) 
annual incidence, and (v) cases/families. 
 
If no prevalence information was available for the disease in the trial location then the prevalence 
for a neighbouring country or another country from the same geographic region was used. For trial 
conducted in US only, prevalence from that country was used. If there was no data from the US, data 
from the following was used (in decreasing order): North America, Europe (region), individual 
European country, Worldwide and other countries. For trials conducted in a single European 
country, data from the following locations were used (in decreasing order): the European country 
where the trial was conducted, Europe (as a region), other European countries, US, North America, 
Worldwide and other countries. For trials conducted in Europe, prevalence from Europe was used. If 
that was not available data from other locations were used, in decreasing order: other European 
countries or US, North America, Worldwide and other countries. Finally, for trials conducted in both 
US and Europe, prevalence data from both US and Europe were used and then ordered by validation 
status and type of prevalence. If either of these were not available data from other geographical 
area, in decreasing order, were used: European countries, North America, Worldwide and other 
countries. In all cases when there were more than one prevalence information, they were ordered 
by validation status and type of prevalence. Note that if only the number of cases/families was 
recorded, the prevalence was assumed to be <1/1,000,000. 
 
Appendix A3  
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< Figure A2 about here > 
 
Appendix A4 
Table A3 Characteristics of rare disease trials conducted in the United States (US) and/or European 
Union (EU) by class of prevalencea. Data are number of trials, m (%), or mean (standard deviation, 
SD). 
  Class of prevalence   
< 1/1,000,000 
(m = 19) 
1-9/1,000,000 
(m = 126) 
1-9/100,000 
(m = 791) 
1-5/10,000 
(m = 631) 
Unknown 
(m = 37)   
m (%) m (%) m (%) m (%) m (%) 
Inclusion criteria 
          
*Gender 
          
 
Both 17 (89) 119 (94) 772 (97) 505 (80) 33 (89)  
Female . . 5 (3) 6 (<1) 111 (17) 1 (2)  
Male 2 (10) 2 (1) 13 (1) 15 (2) 3 (8)             
Accepts healthy 
volunteers? 
          
 
Yes 1 (5) 2 (1) 11 (1) 7 (1) . .  
No 18 (94) 124 (98) 778 (98) 620 (98) 37 (100)  
Missing . . . . 2 (<1) 4 (<1) . .             
*Age categoriesb 
          
 
Children only 2 (10) 11 (8) 65 (8) 42 (6) 2 (5)  
Adults only 1 (5) 3 (2) 45 (5) 68 (10) 1 (2)  
Elderly only . . . . 24 (3) 9 (1) . .  
Children to 
elderly 
9 (47) 36 (28) 107 (13) 69 (10) 11 (29) 
 
Children and 
adults 
2 (10) 16 (12) 42 (5) 31 (4) . . 
 
Adults to 
elderly 
5 (26) 60 (47) 508 (64) 412 (65) 23 (62) 
            
Study designs 
          
Phase of investigationc 
 
Phase 2 16 (84) 92 (73) 602 (76) 450 (71) 28 (75)  
Phase 2/3 3 (15) 6 (4) 30 (3) 23 (3) 4 (10)  
Phase 3 . . 28 (22) 159 (20) 158 (25) 5 (13)             
*Has DMC?d 
          
 
Yes 7 (36) 51 (40) 401 (50) 258 (40) 17 (45)  
No 11 (57) 37 (29) 224 (28) 207 (32) 11 (29)  
Missing 1 (5) 38 (30) 166 (20) 166 (26) 9 (24)             
*FDA regulated intervention?e 
 
Yes 10 (52) 67 (53) 438 (55) 246 (38) 19 (51)  
No 9 (47) 39 (30) 271 (34) 275 (43) 13 (35)  
Missing . . 20 (15) 82 (10) 110 (17) 5 (13)             
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  Class of prevalence   
< 1/1,000,000 
(m = 19) 
1-9/1,000,000 
(m = 126) 
1-9/100,000 
(m = 791) 
1-5/10,000 
(m = 631) 
Unknown 
(m = 37)   
m (%) m (%) m (%) m (%) m (%) 
Is Section 801?f 
          
 
Yes 10 (52) 59 (46) 389 (49) 213 (33) 14 (37)  
No . . 8 (6) 45 (5) 28 (4) 3 (8)  
Missing 9 (47) 59 (46) 357 (45) 390 (61) 20 (54)             
*Intervention model  
Crossover 
assignment 
. . 7 (5) 43 (5) 27 (4) 1 (2) 
 
Factorial 
assignment 
. . . . 5 (<1) 4 (<1) . . 
 
Parallel 
assignment 
7 (36) 32 (25) 284 (35) 264 (41) 7 (18) 
 
Single group 
assignment 
12 (63) 79 (62) 425 (53) 276 (43) 28 (75) 
 
Missing . . 8 (6) 34 (4) 60 (9) 1 (2)             
Masking 
          
 
Double blind 5 (26) 19 (15) 153 (19) 139 (22) 7 (18)  
Single blind 1 (5) 1 (<1) 12 (1) 11 (1) 1 (2)  
Open label 13 (68) 99 (78) 601 (75) 430 (68) 28 (75)  
Missing . . 7 (5) 25 (3) 51 (8) 1 (2)             
Allocation 
          
 
Randomized 7 (36) 35 (27) 320 (40) 319 (50) 9 (24)  
Non-
randomized 
. . 37 (29) 183 (23) 108 (17) 11 (29) 
 
Missing 12 (63) 54 (42) 288 (36) 204 (32) 17 (45)             
Endpoint classification  
Efficacy study 3 (15) 30 (23) 199 (25) 151 (23) 9 (24)  
Safety/ 
efficacy study 
14 (73) 77 (61) 467 (59) 366 (58) 27 (72) 
 
Safety study 1 (5) 4 (3) 39 (4) 16 (2) . .  
Bio-
equivalence 
study 
. . . . 3 (<1) 1 (<1) . . 
 
Pharmacodyn
amics study 
. . . . . . 3 (<1) . . 
 
Pharmacokine
tics study 
. . 1 (<1) 3 (<1) 1 (<1) . . 
 
Pharmacokine
tics/ dynamics 
study 
. . 1 (<1) . . 2 (<1) . . 
 
Missing 1 (5) 13 (10) 80 (10) 91 (14) 1 (2)             
Interventions, facilities and authorities 
*Lead sponsor 
          
 
US Federal . . 2 (1) . . 6 (<1) . .  
Industry 10 (52) 35 (27) 208 (26) 185 (29) 9 (24)  
NIH . . 12 (9) 47 (5) 21 (3) 3 (8)  
Other 9 (47) 77 (61) 536 (67) 419 (66) 25 (67) 
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  Class of prevalence   
< 1/1,000,000 
(m = 19) 
1-9/1,000,000 
(m = 126) 
1-9/100,000 
(m = 791) 
1-5/10,000 
(m = 631) 
Unknown 
(m = 37)   
m (%) m (%) m (%) m (%) m (%)             
*Trial location 
          
 
US only 6 (31) 77 (61) 485 (61) 255 (40) 17 (45)  
EU only 3 (15) 7 (5) 28 (3) 86 (13) 2 (5)  
US and EU 4 (21) 6 (4) 38 (4) 34 (5) 2 (5)  
Single 
European 
country 
6 (31) 36 (28) 240 (30) 256 (40) 16 (43) 
            
*No. of countries where trials run         
 m 19 126 791 631 37 
 Mean 1.53 1.43 1.25 1.70 1.35  
Standard 
deviation, SD 
0.77 1.52 1.10 2.06 1.27 
            
*No. of arms           
 m 19 106 700 523 29 
 Mean 1.53 1.42 1.60 1.66 1.38 
 SD 0.84 0.69 0.85 0.72 0.68 
            
*Year that enrolment to the protocol begins  
< 1990 . . 1 (<1) 2 (<1) 1 (<1) 1 (2)  
1990-1999 . . 6 (4) 40 (5) 47 (7) 2 (5)  
2000-2004 1 (5) 27 (21) 117 (14) 90 (14) 4 (10)  
2005-2009 5 (26) 42 (33) 266 (33) 263 (41) 15 (40)  
2010-2014 11 (57) 49 (38) 328 (41) 210 (33) 14 (37)  
2015 and after 2 (10) . . 25 (3) 14 (2) 1 (2)  
Missing . . 1 (<1) 13 (1) 6 (<1) . .             
Overall recruitment status  
Active, not 
recruiting 
2 (10) 17 (13) 131 (16) 103 (16) 3 (8) 
 
Completed 7 (36) 44 (34) 308 (38) 258 (40) 14 (37)  
Enrolling by 
invitation 
. . 3 (2) 8 (1) 3 (<1) . . 
 
Not yet 
recruiting 
2 (10) 6 (4) 26 (3) 22 (3) 3 (8) 
 
Recruiting 8 (42) 35 (27) 209 (26) 152 (24) 12 (32)  
Suspended . . 2 (1) 1 (<1) 7 (1) . .  
Terminated . . 13 (10) 84 (10) 66 (10) 4 (10)  
Withdrawn . . 6 (4) 24 (3) 20 (3) 1 (2)  
Primary completion duration (years)g 
 
m 19 110 713 534 30  
Mean 2.95 4.16 3.81 3.46 3.27  
SD 2.7 3.35 2.88 2.33 1.75 
Footnote: 
* Covariates considered in the ANOVA/linear regression model as described in Section 2.4 
a Member states of the EU and associated countries. 
b Minimum and maximum age groups are mutually exclusive. Children, term new born infants to 
adolescents up to 18 years; adults, 18-64 years old; and elderly, 65 years or older. 
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  Class of prevalence   
< 1/1,000,000 
(m = 19) 
1-9/1,000,000 
(m = 126) 
1-9/100,000 
(m = 791) 
1-5/10,000 
(m = 631) 
Unknown 
(m = 37)   
m (%) m (%) m (%) m (%) m (%) 
c As defined by the US FDA for trials involving investigational new drugs. 
d Indicate whether or not a data monitoring committee (DMC) has been appointed for this study. 
e Indicate whether or not the trial includes an intervention subject to US Food and Drug Administration 
regulation under section 351 of the Public Health Service Act or any of the following sections of the Federal 
Food, Drug and Cosmetic Act: 505, 510(k), 515, 520(m), and 522. 
f Whether the FDA regulated intervention is an "applicable clinical trial" as defined in US Public Law 110-85, 
Title VIII, Section 801. 
g The difference between enrolment date and the actual primary completion date where the final subject 
was examined or received the intervention for the purpose of data collection for the primary outcome or 
anticipated date where trials were ongoing. 
 
Appendix A5 
Table A4 Fitted mean of sample size and 95% confidence interval (CI) back transformed from 
logarithmic values, type III F statistic and the corresponding p value of the effect of the covariate on 
sample size adjusted by class of prevalence, phase of trial and interaction between prevalence and 
phase. 
Characteristics 
No. of 
trials, m 
Fitted 
mean 95% CI F test p value 
Inclusion criteria 
     
Gender 1148 
  
10.61 <.0001 
 
Both 
 
49.30 (41.85–58.08) 
  
 
Female 
 
58.12 (44.23–76.38) 
  
 
Male 
 
21.09 (14.04–31.69) 
  
       
Age categoriesa 1148 
  
4.52 0.0004 
 
Children only 
 
36.29 (28.03–46.99) 
  
 
Adults only 
 
58.49 (45.34–75.45) 
  
 
Elderly only 
 
89.17 (58.86–135.08) 
  
 
Children and adults 
 
51.94 (39.74–67.87) 
  
 
Children to elderly 
 
44.98 (36.88–54.85) 
  
 
Adults to elderly 
 
50.93 (42.66–60.80) 
  
       
Study designs 
     
Has DMC?b 963 
  
9.94 0.0017 
 
No 
 
42.95 (35.92–51.36) 
  
 
Yes 
 
52.43 (44.06–62.38) 
  
       
FDA regulated intervention?c 1076 
  
4.09 0.0433 
 
No 
 
52.30 (43.72–62.56) 
  
 
Yes 
 
46.20 (38.77–55.06) 
  
       
Intervention model 1114 
  
56.55 <.0001 
 
Crossover assignment 
 
28.63 (21.84–37.53) 
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Characteristics 
No. of 
trials, m 
Fitted 
mean 95% CI F test p value  
Factorial assignment 
 
139.83 (56.36–346.91) 
  
 
Parallel assignment 
 
71.38 (60.45–84.28) 
  
 
Single group assignment 
 
34.28 (29.05–40.46) 
  
       
Interventions, facilities and authorities 
     
Lead sponsor 1148 
  
1.53 0.2041 
 
US Federal 
 
68.43 (30.81–151.99) 
  
 
Industry 
 
46.20 (38.50–55.43) 
  
 
NIH 
 
65.80 (44.80–96.65) 
  
 
Other 
 
49.20 (41.46–58.38) 
  
       
Trial location 1148 
  
7.68 <.0001 
 
US only 
 
42.50 (35.57–50.79) 
  
 
EU only 
 
71.63 (55.99–91.64) 
  
 
US and EU 
 
46.29 (35.40–60.53) 
  
 
Single European country 
 
49.77 (41.55–59.62) 
  
       
No. of countries involved in the trial 1148 1.07d (1.04–1.11) 16.07 <.0001 
       
Year that enrolment to the protocol 
begins 
1141 
  
3.14 0.0081 
 
< 1990 
 
131.48 (34.06–507.57) 
  
 
1990-1999 
 
57.83 (41.44–80.69) 
  
 
2000-2004 
 
63.10 (50.12–79.44) 
  
 
2005-2009 
 
44.61 (37.31–53.34) 
  
 
2010-2014 
 
48.72 (40.92–58.01) 
  
 
2015 and after 
 
49.89 (35.70–69.71) 
  
       
No. of arms 1085 1.39d (1.30–1.49) 83.75 <.0001 
a Minimum and maximum age groups are mutually exclusive. Children, term new born infants to 
adolescents up to 18 years; adults, 18-64 years old; and elderly, 65 years or older. 
b Indicate whether or not a data monitoring committee (DMC) has been appointed for this study. 
c Indicate whether or not the trial includes an intervention subject to US Food and Drug Administration 
regulation under section 351 of the Public Health Service Act or any of the following sections of the Federal 
Food, Drug and Cosmetic Act: 505, 510(k), 515, 520(m), and 522. 
d Estimated coefficient, the estimated increase of sample size for every unit increase of the covariate. 
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Table A5 Fitted mean of sample size and 95% confidence interval (CI), type III F statistic and the 
corresponding p value of the effect of the covariate on sample size adjusted by class of prevalence, 
phase of trial and interaction between class and phase for parallel 2-arm trials only. 
Characteristics 
No. of 
trials, m 
Fitted 
mean 95% CI F test p value 
Inclusion criteria 
     
Gender 354 
  
4.66 0.0101 
30 
 
Characteristics 
No. of 
trials, m 
Fitted 
mean 95% CI F test p value  
Both 
 
64.21 (51.30–80.36) 
  
 
Female 
 
105.11 (70.26–157.26) 
  
 
Male 
 
38.08 (15.93–91.00) 
  
       
Age categoriesa 354 
  
2.32 0.043 
 
Children only 
 
44.44 (29.90–66.05) 
  
 
Adults only 
 
75.84 (53.16–108.21) 
  
 
Elderly only 
 
100.50 (56.18–179.79) 
  
 
Children and adults 
 
73.17 (48.83–109.64) 
  
 
Children to elderly 
 
56.93 (42.19–76.84) 
  
 
Adults to elderly 
 
70.83 (55.34–90.66) 
  
       
Study designs 
     
Has DMC?b 321 
  
8.39 0.004 
 
No 
 
53.90 (41.26–70.41) 
  
 
Yes 
 
72.29 (57.83–90.38) 
  
       
FDA regulated intervention?c 347 
  
2.31 0.1293 
 
No 
 
71.04 (55.51–90.92) 
  
 
Yes 
 
61.37 (48.04–78.39) 
  
       
Interventions, facilities and 
authorities 
     
Lead sponsor 354 
  
1.18 0.3179 
 
US Federal 
 
15.15 (2.72–84.37) 
  
 
Industry 
 
62.54 (48.26–81.04) 
  
 
NIH 
 
69.66 (28.97–167.50 
  
 
Other 
 
67.80 (53.39–86.09) 
  
       
Trial location 354 
  
4.53 0.0039 
 
US only 
 
55.61 (43.34–71.36) 
  
 
EU only 
 
100.14 (69.12–145.08) 
  
 
US and EU 
 
76.58 (51.07–114.83) 
  
 
Single European country 
 
69.98 (54.48–89.90) 
  
       
No. of countries involved in the trial 354 1.07d (1.01–1.13) 5.86 0.016 
       
Year that enrolment to the protocol 
begins 
354 
  
0.83 0.5084 
 
1990-1999 
 
62.53 (28.01–139.61) 
  
 
2000-2004 
 
89.96 (59.68–135.61) 
  
 
2005-2009 
 
64.28 (50.05–82.56) 
  
 
2010-2014 
 
65.55 (51.14–84.04) 
  
 
2015 and after 
 
64.43 (39.24–105.79) 
  
       
31 
 
Characteristics 
No. of 
trials, m 
Fitted 
mean 95% CI F test p value 
Types of arms 351   18.27 <.0001 
 Experimental vs. Placebo  52.82 (41.54–67.17)   
 Experimental vs. Standard  106.78 (83.63–136.33)   
 Experimental vs. Experimental  53.44 (39.86–71.63)   
 Non-experimental vs. Non-
experimental  
 59.78 (45.57–78.43)   
a Minimum and maximum age groups are mutually exclusive. Children, term new born infants to 
adolescents up to 18 years; adults, 18-64 years old; and elderly, 65 years or older. 
b Indicate whether or not a data monitoring committee (DMC) has been appointed for this study. 
c Indicate whether or not the trial includes an intervention subject to US Food and Drug Administration 
regulation under section 351 of the Public Health Service Act or any of the following sections of the Federal 
Food, Drug and Cosmetic Act: 505, 510(k), 515, 520(m), and 522. 
d Estimated coefficient, the estimated increase of sample size for every unit increase of the covariate. 
 
Appendix A7 
Table A6 Fitted mean of sample size and 95% confidence interval (CI), type III F statistic and the 
corresponding p value of the effect of class of prevalence on sample size adjusting for phase and 
interaction between prevalence and phase with adjustment for other covariates. 
Characteristics 
Parallel 2-arm adjusting for other covariatesa 
Single-group (1-arm) adjusting for other 
covariatesb 
N
o
. o
f 
tr
ia
ls
, m
 
Fi
tt
e
d
 m
e
an
 
95% CI F test p value N
o
. o
f 
tr
ia
ls
, m
 
Fi
tt
e
d
 m
e
an
 
95% CI F test p value 
Prevalence class 
   
6.32 0.0004 
   
8.86 <.0001   
< 1/1,000,000 5 45.19 (20.92–97.64) 
  
12 21.15 (7.95–56.26) 
  
  
1-9/1,000,000 14 50.72 (29.96–85.87) 
  
50 70.68 (43.15–115.77) 
  
  
1-9/100,000 154 112.53 (77.92–162.52) 
  
276 84.64 (55.38–129.36) 
  
  
1-5/10,000 146 96.42 (69.18–134.38) 
  
171 143.51 (90.06–228.69) 
  
Phase of investigationc 
   
8.59 0.0036 
   
1.13 0.2873 
  
Phase 2 167 51.75 (33.71–79.44) 
  
455 56.97 (37.66–86.17) 
  
  
Phase 3 152 96.36 (61.60–150.74) 
  
54 74.80 (40.53–138.05) 
  
Prevalence*Phase 
   
1.05 0.3727 
   
5.32 0.0013  
P
h
as
e 
2
 
< 1/1,000,000 3 31.71 (12.42–80.93) 
  
11 29.10 (15.32–55.27) 
  
 
1-9/1,000,000 8 48.03 (25.40–90.80) 
  
39 62.95 (39.30–100.84) 
  
 
1-9/100,000 85 72.78 (49.53–106.94) 
  
244 76.86 (50.96–115.92) 
  
 
1-5/10,000 71 64.72 (45.54–91.98) 
  
161 74.79 (49.48–113.06) 
  
              
P
h
as
e 
3
 
< 1/1,000,000 2 64.41 (20.93–198.25) 
  
1 15.37 (2.61–90.47) 
  
 
1-9/1,000,000 6 53.57 (26.74–107.31) 
  
11 79.36 (40.81–154.35) 
  
 
1-9/100,000 69 174.00 (117.36–257.98) 
  
32 93.21 (56.91–152.67) 
  
 
1-5/10,000 75 143.65 (100.29–205.75) 
  
10 275.36 (147.46–514.19) 
  
a Gender, age, whether or not the trial had a DMC, trial regions, number of countries participating in the trial and types of 
arm. 
b Lead sponsor, trial regions, number of countries participating in the trial and year that enrolment to the protocol begins. 
c As defined by the US FDA for trials involving investigational new drugs. 
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Appendix A8 
Table A7 Fitted mean of sample size and 95% confidence interval (CI), type III F statistic and the 
corresponding p value of the effect of the covariate on sample size adjusted by class of prevalence, 
phase of trial and interaction between class and phase for single-assignment 1-arm trials only. 
Characteristics 
No. of 
trials, m 
Fitted 
mean 95% CI F test p value 
Inclusion criteria 
     
Gender 527 
  
2.58 0.0769 
 
Both 
 
33.38 (25.76–43.24) 
  
 
Female 
 
24.84 (15.86–38.90) 
  
 
Male 
 
20.84 (11.72–37.07) 
  
       
Age categoriesa 527 
  
1.18 0.3184 
 
Children only 
 
27.82 (18.67–41.46) 41.46 
 
 
Adults only 
 
35.18 (23.20–53.36) 53.36 
 
 
Elderly only 
 
56.05 (31.69–99.15) 99.15 
 
 
Children and adults 
 
30.30 (19.48–47.12) 47.12 
 
 
Children to elderly 
 
33.60 (24.87–45.40) 45.4 
 
 
Adults to elderly 
 
32.37 (24.50–42.78) 42.78 
 
       
Study designs 
     
Has DMC?b 450 
  
0.01 0.9328 
 
No 
 
31.87 (24.29–41.82) 
  
 
Yes 
 
32.11 (24.24–42.54) 
  
       
FDA regulated intervention?c 514 
  
1.94 0.1647 
 
No 
 
35.79 (27.16–47.16) 
  
 
Yes 
 
31.87 (24.33–41.75) 
  
       
Interventions, facilities and 
authorities 
     
Lead sponsor 527 
  
4.49 0.004 
 
US Federal 
 
125.86 (49.53–319.80) 
  
 
Industry 
 
31.99 (24.19–42.31) 
  
 
NIH 
 
55.42 (31.66–97.02) 
  
 
Other 
 
31.85 (24.44–41.50) 
  
       
Trial location 527 
  
5.14 0.0017 
 
US only 
 
27.35 (20.71–36.11) 
  
 
EU only 
 
50.43 (35.66–71.32) 
  
 
US and EU 
 
34.32 (22.45–52.48) 
  
 
Single European country 
 
27.81 (20.89–37.03) 
  
       
No. of countries involved in the trial 527 1.12d (1.07–1.18) 19.58 <.0001 
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Characteristics 
No. of 
trials, m 
Fitted 
mean 95% CI F test p value 
Year that enrolment to the protocol 
begins 
523 
  
4.90 0.0002 
 
< 1990 
 
313.70 (53.14–1852.05) 
  
 
1990-1999 
 
26.44 (13.53–51.68) 
  
 
2000-2004 
 
50.47 (36.25–70.28) 
  
 
2005-2009 
 
29.75 (22.55–39.25) 
  
 
2010-2014 
 
31.15 (23.99–40.46) 
  
 
2015 and after 
 
35.79 (21.68–59.08) 
  
a Minimum and maximum age groups are mutually exclusive. Children, term new born infants to 
adolescents up to 18 years; adults, 18-64 years old; and elderly, 65 years or older. 
b Indicate whether or not a data monitoring committee (DMC) has been appointed for this study. 
c Indicate whether or not the trial includes an intervention subject to US Food and Drug Administration 
regulation under section 351 of the Public Health Service Act or any of the following sections of the Federal 
Food, Drug and Cosmetic Act: 505, 510(k), 515, 520(m), and 522. 
d Estimated coefficient, the estimated increase of sample size for every unit increase of the covariate. 
 
 
Appendix A9  
< Figure A8 about here > 
 
Appendix A10 
Table A9 Number of trials by conditions for females and males only and phase of study. 
Gender Conditions Phase 2 Phase 3 
Females only 
  
 
Addison Disease 1 0 
 
Congenital Toxoplasmosis 0 1 
 
Gastroschisis 0 2 
 
Hereditary Breast and Ovarian Cancer Syndrome 1 0 
 
Lymphangioleiomyomatosis 3 0 
 
Ondine Syndrome 0 1 
 
Ovarian Cancer 48 11 
 
Peripartum Cardiomyopathy 1 0 
 
Placental Insufficiency 1 0 
 
Preeclampsia 1 1 
 
Rett Syndrome 5 0 
 
Systemic Sclerosis 1 0 
 
Turner Syndrome 0 1 
Males only 
  
 
Allan-Herndon-Dudley Syndrome 2 0 
 
Barth Syndrome 1 0 
 
Becker Muscular Dystrophy 1 0 
 
Duchenne Muscular Dystrophy 6 2 
 
Fabry Disease 2 0 
34 
 
Gender Conditions Phase 2 Phase 3  
Fragile X Syndrome 4 0 
 
Hemophilia 0 1 
 
Hemophilia A 1 2 
 
Severe Hemophilia A 1 1 
 
X-Linked Hypohidrotic Ectodermal Dysplasia 1 0 
 
 
Appendix A11 
Table A10 List of rare diseases as identified by Orphadata and in AACT but with unknown class of 
prevalence. 
Diseases No. of trials, m (%) 
Allergic bronchopulmonary aspergillosis 1 (2.70) 
Amyloidosis 5 (13.51) 
Arachnoiditis 1 (2.70) 
Aspergillosis 5 (13.51) 
Cutaneous mastocytosis 1 (2.70) 
Erdheim-Chester disease 2 (5.40) 
Fibrous dysplasia of bone 2 (5.40) 
Germ cell tumor 3 (8.10) 
Heparin-induced thrombocytopenia 1 (2.70) 
Hereditary pulmonary alveolar proteinosis 1 (2.70) 
Idiopathic nephrotic syndrome 1 (2.70) 
Intrahepatic cholestasis of pregnancy 1 (2.70) 
Kawasaki disease 1 (2.70) 
Ligneous conjunctivitis 1 (2.70) 
Loiasis 1 (2.70) 
POEMS syndrome 2 (5.40) 
Precocious puberty 3 (8.10) 
Solitary fibrous tumor 1 (2.70) 
Synovial sarcoma 1 (2.70) 
Thymic carcinoma 2 (5.40) 
Zygomycosis 1 (2.70) 
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Figure A2 A breakdown of trials in ClinicalTrials.gov included in final analyses. 
Footnote: a The primary purpose of the trial; b A treatment-purpose trial is to evaluate one or more interventions for 
treating a disease, syndrome or condition; c Phase of investigation as defined by the US FDA; d For trials that do not 
involve drug or biologic products (e.g., behavioural interventions); e Primary disease or condition being studied in the 
trial. The terms of the conditions should follow the National Library of Medicine’s Medical Subject Headings (MeSH) 
where possible; f Trials studying non-rare disease(s)/condition(s); g Trials studying both rare and non-rare 
disease(s)/condition(s); h Number of rare disease(s)/condition(s) being studied in a trial. i Estimated prevalence from 
Orphanet; j The rare disease/condition has no prevalence data from Orphanet. 
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